Blood Screening Market Size, Share, Industry, Forecast and outlook (2024-2031)

Global Blood Screening Market is segmented By Product Type (Instruments  (Outright Purchase, Rental Purchase), Reagents & Kits (NAT Reagents & Kits, ELISA Reagents & Kits, Other Reagents),  Software and Services), By Technology (Next-Generation Sequencing, Nucleic Acid Test, Enzyme-Linked Immunosorbent Assay (ELISA, By Platform, ELISA, By Generation, Western Blot Assay, Rapid Tests, others)), By End-Users (Hospitals, Blood Banks, others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031

Report Overview

Global Blood Screening Market reached US$ YY billion in 2022 and is expected to reach US$ YY  million by 2030 growing at a CAGR of YY% during the forecast period 2024-2031.

Blood screening tests are performed to identify infection signs in order to stop the distribution of contaminated blood and blood components for clinical use. A blood screening test is done to detect potential health disorders or diseases in people who do not have any symptoms of the disease.

Blood screening strategies are designed to assure the safety of blood units, but should not be used for notifying blood donors of reactive test results. Various technologies are used in blood screening tests which include next-generation sequencing, nucleic acid tests, and ELISA.

Market Summary

For more details on this report Request for Sample

Market Dynamics

Increasing launches of blood screening tests

Blood screening tests are performed on a blood sample to provide valuable information and diagnose specific medical conditions. The increasing number of product launches for blood screening tests acts as a significant driver for market growth. Also, many significant companies play a major role in the advancements of the market by launching new blood screening tests and kits.

For instance, in October 2023, Delfi Diagnostics launched a blood-based lung cancer screening test. It aims to provide a more convenient detection method and one that’s capable of reaching a greater number of people than the current standard.

Additionally, in August 2023, Quest Diagnostics introduced its AD-Detect test for Alzheimer’s disease in the United States by making it the first blood-based biomarker test available for consumers to purchase and assess the potential risks of developing Alzheimer’s disease.

Furthermore, the global blood screening market is driven by various factors like rising blood donations, and an increase in the incidence of infectious diseases is expected to drive the market in the forecast period.

The stringent regulatory approvals and high cost of blood screening equipment

Stringent regulatory requirements can slow the approval and adoption of new blood screening technologies or tests. Also, the high cost associated with blood screening equipment can hamper the market growth. 

Market Segment Analysis

The global blood screening market is segmented based on product type, technology, end users, and region.

Reagents and kits accounted for approximately 48.4% of the market share 

The anti-A, anti-B, and anti-A, B reagents are used in the red blood cell determination of the ABO blood group. They are used to determine the absence or presence of erythrocytic antigens A or B on the surface of human red blood cells. Reagents and kits are expected to hold the largest market share over the period forecast owing to the high requirement for reagents, kits, and product launches. 

For instance, in June 2023, Sysmex launched an assay kit to identify Amyloid Beta (Aβ) accumulation in the brain that causes  Alzheimer’s disease by using a small amount of blood. 

Additionally, in July 2021, Ortho Clinical Diagnostics launched its VITROS Immunodiagnostic Products IL-6 Reagent Pack which is the latest addition to Ortho's VITROS Critical Care blood screening menu.

Market Geographical Share

North America is expected to hold a significant position in the global blood screening market share

The global blood screening market is segmented into North America, Europe, Asia Pacific, South America, Middle East, and Africa. 

North America has maintained a significant market proportion due to factors such as the rising blood transfusion rates, and product launches, this trend is anticipated to continue throughout the forecast period.

For instance, according to the American Red Cross, in the United States, an estimated 10,000 units of plasma, roughly 7,000 units of platelets, and 36,000 units of red blood cells are needed per day. In the United States, more than 21 million blood components are transfused annually.

Additionally, in September 2023, Oxford BioDynamics, Plc. launched its 94% accurate EpiSwitch prostate screening blood test for men with prostate cancer risk. 

COVID-19 Impact Analysis 

The COVID-19 pandemic has had a significant impact on the global blood screening market. The onset of the pandemic in early 2020 led to widespread lockdowns and restrictions, impacting regular diagnoses, treatments, device launches, and consultations worldwide. With the outbreak of the pandemic, many pharmaceutical or medical device manufacturing units faced labor shortages and were unable to travel to work due to lockdown restrictions. Therefore, owing to the above factors, the blood screening market is expected to be moderately affected over the forecast period.

Market Competitive Landscape

The major global players in the market include Bio-Rad Laboratories, Inc., Grifols S.A, Abbott Laboratories, F. Hoffmann-La Roche, Siemens Healthineers, Biomérieux, Thermo Fisher Scientific, Inc., Ortho Clinical Diagnostics, Inc., Becton, Dickinson, and Company, Beckman Coulter (Danaher Corporation). among others.

Key Developments

• In March 2023, H.U. Group Holdings Inc. introduced the Lumipulse G NfL CSF and Lumipulse G NfL Blood assays for the fully automated random-access LUMIPULSE G immunoassay systems. These CLEIA (chemiluminescent enzyme immunoassay) assays allow for the quantitative measurement of Neurofilament light (NfL) in human cerebrospinal fluid (CSF) and plasma.
• In June 2021, Grail launched the Galleri blood screening test which is a multi-cancer screening capable of detecting many cancers. 

Why Purchase the Report?

• To visualize the global blood screening market segmentation based on product type, technology, end users and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development. 
• Excel data sheet with numerous data points of blood screening market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global blood screening market report would provide approximately 61 tables, 58 figures, and 185 Pages.

Target Audience 2024

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies